Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426806 | 0.83 | ALDH1A1 (0.55) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL274588 | 0.79 | MAOB (0.38) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL2958548 | 0.73 | ALDH1A1 (0.45) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL2448169 | 0.73 | ALDH1A1 (0.45) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL1502203 | 0.71 | BCL2L1 (0.50) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL458242 | 0.71 | CYP1A2 (0.50) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL457757 | 0.71 | ALDH1A1 (0.50) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL454694 | 0.71 | ALDH1A1 (0.43) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 | |
| SCHEMBL22130125 | 0.71 | ADRB2 (0.44) | HSD17B10ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL143471 | 0.69 | ALDH1A1 (0.90) | HSD17B10TAAR1CYP3A4TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| JP-2011528040-A | — | — | 2011-11-10 | — | — | JP | claimed |
| JP-2011528039-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2303881-A2 | FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
| WO-2010009139-A2 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | claimed |
| CN-112105611-A | Pharmaceutical combination comprising a Histone Deacetylase (HDAC) inhibitor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer | 4SC股份公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-112055589-A | Combination comprising an HDAC inhibitor, a LAG-3 inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor for the treatment of cancer | 4SC股份公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-112004535-A | Combination comprising an HDAC inhibitor and a CD137 agonist for cancer therapy | 4SC股份公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-111432884-A | Combination of HDAC inhibitors with immune checkpoint modulators for cancer therapy | 4SC股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-2627627-B1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2013-12-05 | — | — | US | disclosed |
| EP-2627627-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012048887-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | ADH1C, ADH1A, ADH5 | HSD17B10 208/4885TAAR1 1005/4885CYP3A4 52/4885 |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | HSD17B10 1643/4885TAAR1 4682/4885CYP3A4 2598/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | HSD17B10 958/4885TAAR1 4647/4885CYP3A4 3694/4885 |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | ADH1C, ADH1A, ADH5 | HSD17B10 208/4885TAAR1 1005/4885CYP3A4 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.